Magnolia to evaluated the likelihood that a drug compendia would support an off-label dose for a drug with an FDA-approved maximum dose, and helped the client obtain stronger payer coverage with a compendia submission.
A client needed to develop an algorithm to identify patients at risk for chronic obstructive pulmonary disease (COPD) exacerbations via structured and unstructured EHR data to help clinicians optimize treatments. Magnolia was able to identify patients more precisely through Deep6 AI data than existing algorithms that use claims data alone.
A medium pharmaceutical company was launching a new oral drug in the diabetes space and wanted to understand how having specific income criteria for their commercial copay program would affect patient enrollment and the costs of program operation.
A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.
A small technology company developed an AI-assisted platform that is used to improve accuracy of a CV diagnostic tool. The company asked Magnolia to gather payer feedback on clinical evidence for the platforms and provide insights on future coverage and reimbursement.
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.
A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data.
A biopharma company needed an inpatient coding analysis for their new medication.